UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 41.

Leinweber, N; Dziunycz, P J; French, L E; Wüthrich, R; Serra, A L; Hofbauer, G F L (2016). Considerable loss of information on skin cancer occurrence and non-adherence to clinical practice guideline in renal transplant recipients. Journal of the European Academy of Dermatology and Venerology, 30(8):1399-1401.

Gerber, S R; Seifert, Burkhardt; Inci, I; Serra, A L; Kohler, M; Benden, C; Hofbauer, G F L; Schuurmans, M M (2015). Exposure to moxifloxacin and cytomegalovirus replication is associated with skin squamous cell carcinoma development in lung transplant recipients. Journal of the European Academy of Dermatology and Venerology, 29(12):2451-2457.

Stimpfle, D W; Serra, A L; Wüthrich, R P; French, L E; Braun, R P; Hofbauer, G F L (2015). Spectophotometric intracutaneous analysis: an investigation on photodamaged skin of immunocompromised patients. Journal of the European Academy of Dermatology and Venerology, 29(6):1141-1147.

Su, Z; Wang, X; Gao, X; Liu, Y; Pan, C; Hu, H; Beyer, R P; Shi, M; Zhou, J; Zhang, J; Serra, A L; Wüthrich, R P; Mei, C (2014). Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease. Journal of Internal Medicine, 276(5):470-485.

Bouwes Bavinck, J N; Harwood, C A; Genders, R E; Wisgerhof, H C; Plasmeijer, E I; Mitchell, L; Olasz, E B; Mosel, D D; Pokorney, M S; Serra, A L; Feldmeyer, L; Baumann Conzett, K; Piaserico, S; Belloni Fortina, A; Jahn, K; Geusau, A; Gerritsen, M J P; Seckin, D; Gulec, A T; Cetkovska, P; Ricar, J; Imko-Walczuk, B; Proby, C M; Hofbauer, G F L (2014). Pain identifies squamous cell carcinoma in organ transplant recipients: the SCOPE-ITSCC PAIN study. American Journal of Transplantation, 14(3):668-676.

Bühler, M N; Feldmeyer, L; Wüthrich, R P; French, L E; Djamei, V; Serra, A L; Hofbauer, G F L (2013). Die edukative Website Dermaguard zur Präventiontion von Hautkrebs nach Organtransplantation. Praxis, 102(23):1415-1420.

Krauer, F; Ahmadli, U; Kollias, S; Bleisch, J; Wüthrich, R P; Serra, A L; Poster, D (2012). Growth of arachnoid cysts in patients with autosomal dominant polycystic kidney disease: serial imaging and clinical relevance. Clinical Kidney Journal, 5(5):405-411.

Warnock, D G; Ortiz, A; Mauer, M; Linthorst, G E; Oliveira, J P; Serra, A L; Marodi, L; Mignani, R; Vujkovac, B; Beitner-Johnson, D; Lemay, R; Cole, J A; Svarstad, E; Waldek, S; Germain, D P; Wanner, C (2012). Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrology, Dialysis, Transplantation, 27(3):1042-1049.

Pavik, I; Jaeger, P; Ebner, L; Poster, D; Krauer, F; Kistler, A D; Rentsch, K; Andreisek, G; Wagner, C A; Devuyst, O; Wüthrich, R P; Schmid, C; Serra, A L (2012). Soluble Klotho and autosomal dominant polycystic kidney disease. Clinical Journal of the American Society of Nephrology, 7(2):248-257.

Kistler, A D; Siwy, J; Breunig, F; Jeevaratnam, P; Scherl, A; Mullen, W; Warnock, D G; Wanner, C; Hughes, D A; Mischak, H; Wüthrich, R P; Serra, A L (2011). A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy. PLoS ONE, 6(6):e20534.

Raina, S; Honer, M; Krämer, S D; Liu, Y; Wang, X; Segerer, S; Wüthrich, R P; Serra, A L (2011). Anti-VEGF antibody treatment accelerates polycystic kidney disease. American Journal of Physiology. Renal Physiology, 301(4):F773-F783.

Pavik, I; Jaeger, P; Kistler, A D; Poster, D; Krauer, F; Cavelti-Weder, C; Rentsch, K M; Wüthrich, R P; Serra, A L (2011). Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney International, 79(2):234-240.

Henschkowski, J; Bischoff-Ferrari, H A; Wüthrich, R P; Serra, A L (2011). Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney & Blood Pressure Research, 34(2):97-103.

Hofbauer, G F L; Attard, N R; Harwood, C A; McGregor, J M; Dziunycz, P; Iotzova-Weiss, G; Straub, G; Meyer, R; Kamenisch, Y; Berneburg, M; French, L E; Wüthrich, R P; Karran, P; Serra, A L (2011). Reversal of UVA Skin Photosensitivity and DNA Damage in Kidney Transplant Recipients by Replacing Azathioprine. American Journal of Transplantation, 12(1):218-225.

Davies, D M; de Vries, P J; Johnson, S R; McCartney, D L; Cox, J A; Serra, A L; Watson, P C; Howe, C J; Doyle, T; Pointon, K; Cross, J J; Tattersfield, A E; Kingswood, J C; Sampson, J R (2011). Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clinical Cancer Research, 17(12):4071-4081.

Serra, A L; Poster, D; Kistler, A D; Krauer, F; Raina, S; Young, J; Rentsch, K M; Spanaus, K S; Senn, O; Kristanto, P; Scheffel, H; Weishaupt, D; Wüthrich, R P (2010). Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. New England Journal of Medicine, 363(9):820-829.

Serra, A L; Poster, D; Wüthrich, R P (2010). Autosomal-dominante polyzystische Nierenerkrankung : Neue therapeutische Ansätze. Der Nephrologe, 5(5):404-411.

Wüthrich, R P; Kistler, A D; Serra, A L (2010). Impact of Mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease. Transplantation Proceedings, 42(9 Supp):S44-S46.

Kistler, A D; Serra, A L (2010). Neue diagnostische Aspekte bei zystischen Nierenerkrankungen. Der Nephrologe, 5(5):375-383.

Wanner, C; Oliveira, J P; Ortiz, A; et al; Serra, A L (2010). Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry. Clinical Journal of the American Society of Nephrology, 5(12):2220-2228.

Kistler, A D; Mischak, H; Poster, D; Dakna, M; Wüthrich, R P; Serra, A L (2009). Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney International, 76(1):89-96.

Serra, A L. Mammalian Target of Rapamycin (mTOR)-mediated Effect on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD). 2009, University of Zurich, Faculty of Medicine.

Grimmelt, A C; Cohen, C D; Fehr, T; Serra, A L; Wüthrich, R P (2009). Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clinical Nephrology, 71(2):125-129.

Kistler, A D; Poster, D; Krauer, F; Weishaupt, D; Raina, S; Senn, O; Binet, I; Spanaus, K; Wüthrich, R P; Serra, A L (2009). Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney International, 75(2):235-241.

Wüthrich, R P; Serra, A L; Kistler, A D (2009). Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney & Blood Pressure Research, 32(5):380-387.

Serra, A L; Wüthrich, R P (2009). Autosomal dominante polyzystische Nierenerkrankung (ADPKD). Pathogenese, Klinik und neue Therapieansätze. Swiss Medical Forum, 2009(47):854-858.

Kistler, A D; Poster, D; Wüthrich, R P; Serra, A L (2009). Hydronephrosis in autosomal dominant polycystic kidney disease. Kidney International, 76(12):1297.

Poster, D; Kistler, A D; Krauer, F; Blumenfeld, J D; Rennert, H; Weishaupt, D; Wüthrich, R P; Serra, A L (2009). Kidney function and volume progression in unilateral autosomal dominant polycystic kidney disease with contralateral renal agenesis or hypoplasia: a case series. American Journal of Kidney Diseases, 54(3):450-458.

Wüthrich, R P; Serra, A L (2009). Mammalian target of rapamycin and autosomal dominant polycystic kidney disease. Transplantation Proceedings, 41(6 Supp):S18-S20.

Wu, M; Arcaro, A; Varga, Z; Vogetseder, A; Le Hir, M; Wüthrich, R P; Serra, A L (2009). Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. American Journal of Physiology. Renal Physiology, 297(6):F1597-F1605.

Serra, A L; Wüthrich, R P (2009). Rapamycin: eine neue Therapieoption bei autosomal dominanter polyzystischer Nierenerkrankung (ADPKD)? Praxis, 98(25):1511-1516.

Serra, A L; Kistler, A D; Poster, D; Krauer, F; Senn, O; Raina, S; Pavik, I; Rentsch, K; Regeniter, A; Weishaupt, D; Wüthrich, R P (2009). Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 24(11):3334-3342.

Hofbauer, G F L; Marcollo Pini, A; French, L E; Wüthrich, R P; Serra, A L (2009). mTOR Inhibitoren bremsen gutartige und bösartige vaskuläre Proliferation am Beispiel von Kaposisarkom und Angiofibrom bei tuberöser Sklerose. Dermatologica Helvetica, 21:17-18.

Serra, A L; Braun, S C; Starke, A; Savoca, R; Hersberger, M; Russmann, S; Corti, N; Wüthrich, R P (2008). Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. American Journal of Transplantation, 8(4):803-810.

Serra, A L; Wüthrich, R P (2008). Use of Cinacalcet to Control Hyperparathyroidism: Treatment with cinacalcet has been shown to be safe and effective in treating primary, secondary, and tertiary hyperparathyroidism. Review of Endocrinology, 2(2):41-45.

Serra, A L; Wuhrmann, C; Wüthrich, R P (2008). Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. American Journal of Kidney Diseases, 52(6):1151-1157.

Berthier, C C; Wahl, P R; Le Hir, M; Wagner, U; Rehrauer, H; Wüthrich, R P; Serra, A L (2008). Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Nephrology, Dialysis, Transplantation, 23(3):880-889.

Hofbauer, G F L; Marcollo-Pini, A; Corsenca, A; Kistler, A D; French, L E; Wüthrich, R P; Serra, A L (2008). The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. British Journal of Dermatology, 159(2):473-475.

Serra, A L; Wüthrich, R P (2008). Wenn Zysten die Niere zerstöre. Ärztliche Praxis Urologie:18-21.

Wahl, P R; Le Hir, M; Vogetseder, A; Arcaro, A; Starke, A; Waeckerle-Men, Y; Serra, A L; Wuthrich, R P (2007). Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology, 12(4):357-363.

Serra, A L; Kistler, A D; Poster, D; Struker, M; Wüthrich, R P; Weishaupt, D; Tschirch, F (2007). Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrology, 8:13.

This list was generated on Tue Jul 25 02:59:36 2017 CEST.